Literature DB >> 7523202

Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy.

A Kriplani1, K Buckshee, V L Bhargava, D Takkar, A C Ammini.   

Abstract

In this report we describe 32 pregnancies complicated by hyperthyroidism cared for over a 7-year period at AIIMS, New Delhi. In 6 cases hyperthyroidism was diagnosed during pregnancy; others were diagnosed before conception and were on antithyroid therapy during pregnancy. For control of thyrotoxicosis thiourea derivatives, carbimazole (CMZ) and propylthiouracil (PTU), were both used. The dosage of antithyroid drugs could be decreased or stopped in the third trimester in only 28% cases, while 50% cases did not require any change in the dosage during gestation and 21% required an increase in dosage with advancing gestation to control thyrotoxicosis. Maternal and fetal complications included preterm labour (25%), PIH (22%), thyroid crisis (9%) and intrauterine growth retardation (13%). Thyroid status of neonates was found abnormal in 9% cases, including 1 case (3%) of neonatal thyrotoxicosis with goitre and 2 (6%) cases of neonatal hypothyroidism. One maternal death occurred due to thyroid storm. No case of stillbirth or perinatal death occurred in the present study. In our experience of 32 cases maternal and fetal complications are reported with increased frequency, requiring close surveillance of thyroid status to maintain euthyroidism and intensive fetal monitoring during pregnancy to achieve good maternal and perinatal outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523202     DOI: 10.1016/0028-2243(94)90276-3

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  18 in total

Review 1.  Hyperthyroidism and pregnancy.

Authors:  Helen Marx; Pina Amin; John H Lazarus
Journal:  BMJ       Date:  2008-03-22

2.  Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.

Authors:  E Gianetti; L Russo; F Orlandi; L Chiovato; M Giusti; S Benvenga; M Moleti; F Vermiglio; P E Macchia; M Vitale; C Regalbuto; M Centanni; E Martino; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

3.  Definition and Multiple Factors of Recurrent Spontaneous Abortion.

Authors:  Xiaolin La; Wenjuan Wang; Meng Zhang; Li Liang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Low Birth Weight in Children Born to Mothers with Hyperthyroidism and High Birth Weight in Hypothyroidism, whereas Preterm Birth Is Common in Both Conditions: A Danish National Hospital Register Study.

Authors:  Stine Linding Andersen; Jørn Olsen; Chun Sen Wu; Peter Laurberg
Journal:  Eur Thyroid J       Date:  2013-05-16

Review 5.  Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.

Authors:  L Bartalena; F Bogazzi; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

Review 6.  Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus.

Authors:  P Atkins; S B Cohen; B J Phillips
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

Review 7.  Hyperthyroidism during pregnancy.

Authors:  Miho Inoue; Naoko Arata; Gideon Koren; Shinya Ito
Journal:  Can Fam Physician       Date:  2009-07       Impact factor: 3.275

8.  Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: a controlled cohort study.

Authors:  Hila Rosenfeld; Asher Ornoy; Svetlana Shechtman; Orna Diav-Citrin
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

9.  Sensory neuron sodium current requires nongenomic actions of thyroid hormone during development.

Authors:  Marc A Yonkers; Angeles B Ribera
Journal:  J Neurophysiol       Date:  2008-09-17       Impact factor: 2.714

Review 10.  Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy.

Authors:  M Tonacchera; L Chiovato; L Bartalena; A F Cavaliere; P Vitti
Journal:  J Endocrinol Invest       Date:  2019-11-29       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.